Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Rapport Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$38.4

+3.19 (+9.06%)

D 39Pipeline Score Richly Valued Biotech · Clinical
Market Cap
1.80 B
EPS
-2.60
P/E Ratio
-
Value Trade
7.30 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    20.00 M

  • R&D Expenses

    32.72 M

  • Operating CF

    -13.06 M

  • Total Assets

    497.60 M

  • Total Liabilities

    26.09 M

  • Equity

    471.51 M

  • D/E Ratio

    12,345

1.07 %
Week
0.91 %
1 Month
27.09 %
3 Month
41.75 %
6 Month
109.56 %
5 Year
109.56 %
All Time
Cash Data
Healthy

  • Cash Position

    476.78 M

  • Monthly Burn

    4.35 M

  • Runway

    108.4 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 7, 2026
Overview
Volume
255.65 K
52 Week Range
7.73 - 42.27
% held by Insiders
40.51 %
% held by Institutions
76.17 %
Enterprise Value
1.34 B
Total Shares
47.81 M
Short %
8.41 %
Float Shares
29.26 M
Company Description
HQ: 99 HIGH STREET, BOSTON, MA, 02...
Employees:84
https://www.rapportrx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 topline data readout example
RAP-219 Bipolar Mania
Phase 2
—
Small Molecules
Psychiatric Disorders
RAP-219 Bipolar Mania
Phase 2
—
Small Molecules
Psychiatric Disorders
RAP-219 Bipolar Mania
Phase 2
—
Small Molecules
Psychiatric Disorders
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D39
Pipeline Score
$193M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 50%
Micro Cap
(rank 453 of 905)
Percentile Rank
Rapport Therapeutics, Inc. faces pipeline headwinds (39/100), with $482M risk-adjusted pipeline value, led by RAP-219 in Focal Epilepsy (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
RAP-219
Small molecule		Focal SeizurePhase 3NCT0756388144% $482M RECRUITING 645 VERY_FAST C (58) Sep 1, 2029 -LOW
May 29, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in RAPP
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
RAPP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RAPP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RAPP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
RAPP Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
RAPP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-21 0.00 0 - - - - - -
2026-08-21 0.00 0 - - - - - -
2026-08-21 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Rapport Therapeutics, Inc. (RAPP) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How RAPP ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Epilepsy #3 of 15 PHASE 3 RAP-219
XENE PRAX NPCE
$12.0B 0.85 CONTENDER
Bipolar Disorder #7 of 12 PHASE 2 RAP-219
BMY ABBV ALKS
$10.5B 0.92 FOLLOWER